Monte Rosa Therapeutics reports Phase 1 data showing 80‑90% NEK7 degradation with biomarker improvements
Monte Rosa Therapeutics announced positive results from its Phase 1 GFORCE‑1 trial of the oral molecular glue MRT‑8102 in 108 obese subjects at elevated cardiovascular risk. The drug achieved roughly 80‑90% median NEK7 degradation across three dose levels and lowered multiple inflammatory and thrombogenic biomarkers without any serious adverse events. The company plans to start Phase 2 studies in coronary artery disease, gout and hidradenitis suppurativa during 2026‑2027.
Why it matters
The company expects to move MRT‑8102 into Phase 2 trials in the first half of 2027 for coronary disease and in late‑2026/early‑2027 for gout and hidradenitis suppurativa, indicating continued pipeline advancement. The safety profile, with no serious adverse events, supports further development and could influence investor sentiment toward GLUE.
Key facts
- 1The Phase 1 GFORCE‑1 trial enrolled 108 obese subjects with elevated cardiovascular disease risk. rttnews.com
- 2Participants received once‑daily MRT‑8102 at 5 mg, 20 mg or 40 mg for four weeks. rttnews.com
- 3Median NEK7 degradation was approximately 80% to 90% across all dose levels. rttnews.com
- 4Calprotectin, S100A12 and serum amyloid A declined by median values of 56%, 46% and 51% respectively. rttnews.com
- 5HMGB1 and IL‑1ß decreased by median reductions of 40% and 37% among subjects with high baseline levels. rttnews.com
- 6Fibrinogen declined by a median of 28%; IL‑6 and hsCRP fell by 54% and 85% respectively. rttnews.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.